Home ›
Entities
› academia
› Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2− Advanced Breast Cancer From a US Payer Perspective
Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2− Advanced Breast Cancer From a US Payer Perspective
Research article (Clinical Breast Cancer, 2015) · cited 28× · AI/ML
Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2− Advanced Breast Cancer From an US Payer Perspective
Summary
Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2− Advanced Breast Cancer From an US Payer Perspective is a scholarly article[1].
Key Facts
Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2− Advanced Breast Cancer From an US Payer Perspective's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2− Advanced Breast Cancer From a US Payer Perspective. Retrieved May 24, 2026, from https://4ort.xyz/entity/economic-evaluations-of-everolimus-versus-other-hormonal-therapies-in-the-treatment-of-hr-her2-advanced-breast-cancer-fr
MLA“Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2− Advanced Breast Cancer From a US Payer Perspective.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/economic-evaluations-of-everolimus-versus-other-hormonal-therapies-in-the-treatment-of-hr-her2-advanced-breast-cancer-fr.
BibTeX@misc{4ortxyz_economic-evaluations-of-everolimus-versus-other-hormonal-therapies-in-the-treatment-of-hr-her2-advanced-breast-cancer-fr_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2− Advanced Breast Cancer From a US Payer Perspective}}, year = {2026}, url = {https://4ort.xyz/entity/economic-evaluations-of-everolimus-versus-other-hormonal-therapies-in-the-treatment-of-hr-her2-advanced-breast-cancer-fr}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2− Advanced Breast Cancer From a US Payer Perspective — https://4ort.xyz/entity/economic-evaluations-of-everolimus-versus-other-hormonal-therapies-in-the-treatment-of-hr-her2-advanced-breast-cancer-fr (retrieved 2026-05-24)
